Business
BioVie Announces Partnership with the American Liver Foundation
Campaign to Improve Education on Ascites Due to Liver Cirrhosis and Raise Awareness of BioVie’s Phase 2b Study of BIV201 for Refractory Ascites RENO, Nev.,
About this update from Biovie Inc.
[{"type":"text","content":"Campaign to Improve Education on Ascites Due to Liver Cirrhosis and Raise Awareness of BioVie’s Phase 2b Study of BIV201 for Refractory Ascites\nRENO, Nev., Dec. 09, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that the Company is partnering with the American Liver Foundation (ALF) in an educational campaign about chronic liver cirrhosis and its complications and to raise awareness among potential patients and healthcare providers about the Company’s Phase 2b Study of BIV201 (continuous infusion terlipressin). The trial— A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients with Cirrhosis and Refractory Ascites —is being conducted at ten prestigious research centers in the U.S. (NCT04112199). “We are grateful to be working with the ALF on this awareness campaign,” said Cuong V. Do, CEO of BioVie. “Due to the rapid increase in non-alcoholic steatohepatitis (NASH) and other ongoing causes of liver cirrhosis, the serious complication of ascites is placing a growing burden on the U.S healthcare system. Our goal for this program is to help improve the understanding among potential patients and the medical community of disease-related conditions such as ascites and hepatorenal syndrome and to evaluate more candidates for enrollment in our clinical development program.” “Our mission is to provide education, advocacy and other support services to everyone whose life is impacted by liver diseases,” said Lorraine Stiehl, CEO of the American Liver Foundation. “We are grateful for the support of our industry partners and pleased to work with BioVie to enhance their efforts to make a difference in the lives of cirrhotic patients with refractory ascites.” Ascites is a common complication of advanced liver cirrhosis involving the accumulation of large volumes of fluid in the abdomen, often exceeding 5 liters, due to liver and kidney dysfunction. An estimated 20,000 Americans suffer from refractory ascites, which means that their ascites no longer responds to off-label diuretic therapy, or they cannot tolerate these drugs. The FDA has never approved a drug for the treatment of ascites, and once patients reach the...